Keeping viral vector manufacturing in-house: strategic considerations for gene therapy biotechs

In by

Spotlight Article

Interview

TIMOTHY J MILLER

Latest Developments in Viral and Non-Viral Vector Manufacturing

Tim Miller Abeona

TIMOTHY J MILLER PhD, is co-Founder, President and Chief Scientific Officer of Abeona Therapeutics Inc. He has over 20 years of business development, scientific research, product development and clinical operations expertise, with a focus on transitioning novel biotherapeutics through pre-clinical phases and Phase 3 human clinical trials. As a C-level executive in public and private companies, he has driven multiple inflection points through innovation and operational excellence in rare disease companies. Dr Miller was President and CEO of Red5 Pharmaceuticals from 2013 until 2015 and was CEO-in-Residence at BioEnterprise Inc. in 2015. He was Senior Director of Product Development at SironRX Therapeutics from 2010 to 2013. Between 1996 and 2010 Dr Miller held various positions at several biotech companies focusing on gene therapy and regenerative medicine. Dr Miller earned his PhD in Pharmacology with a focus on gene therapy/cystic fibrosis from Case Western University. He also holds a BS in Biology and MS in Molecular Biology from John Carroll University (Cleveland, OH, USA).

DOI: 10.18609/cgti.2018.095
Citation: Cell Gene Therapy Insights 2018; 4(10),965-968
Open access

This content is restricted to registered users. Click here to Register or Login here.